prucalopride: a 5-HT4 agonist enterokinetic compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 3052762 |
| CHEMBL ID | 117287 |
| CHEBI ID | 135552 |
| SCHEMBL ID | 16952 |
| MeSH ID | M0360790 |
| Synonym |
|---|
| gtpl243 |
| r-93877 |
| r-093877 |
| prucalopride |
| CHEBI:135552 |
| 4-amino-5-chloro-2,3-dihydro-benzofuran-7-carboxylic acid [1-(3-methoxy-propyl)-piperidin-4-yl]-amide |
| bdbm50122872 |
| L000891 |
| CHEMBL117287 , |
| r093877 |
| 179474-81-8 |
| D09205 |
| prucalopride (usan/inn) |
| 4-amino-5-chloro-n-[1-(3-methoxypropyl)piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide |
| A25458 |
| motegrity |
| 4-amino-5-chloro-n-(1-(3-methoxypropyl)-4-piperidinyl)-2,3-dihydro-1-benzofuran-7-carboxamide |
| resotrans |
| 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]-7-benzofurancarboxamide |
| AKOS015951096 |
| 4-amino-5-chloro-2,3-dihydro-n-(1-(3-methoxypropyl)-4-piperidyl)-7-benzofurancarboxamide |
| prucalopride [usan:inn:ban] |
| unii-0a09iuw5tp |
| 0a09iuw5tp , |
| FT-0674128 |
| BCPP000099 |
| NCGC00253867-01 |
| PB31402 |
| AM84628 |
| 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidyl]-7-benzofurancarboxamide |
| prucalopride [usan] |
| prucalopride [mart.] |
| prucalopride [inn] |
| prucalopride [mi] |
| prucalopride [who-dd] |
| prucalopride [ema epar] |
| S2875 |
| HY-14151 |
| SCHEMBL16952 |
| cas-179474-81-8 |
| dtxsid5057670 , |
| dtxcid2031459 |
| tox21_113885 |
| NCGC00253867-02 |
| 4-amino-5-chloro-n-[1-(3-methoxypropyl)-4-piperidyl]-2,3-dihydrobenzofuran-7-carboxamide |
| 4-amino-5+k445-chloro-2,3-dihydro-benzofuran-7-carboxylic acid [1-(3-methoxy-propyl)-piperidin-4-yl]-amide |
| 4-amino-5-chloro-n-(1-(3-methoxypropyl)piperidin-4-yl)-2,3-dihydrobenzofuran-7-carboxamide |
| AC-23945 |
| DB06480 |
| EX-A1333 |
| SR-01000945275-1 |
| sr-01000945275 |
| HMS3651F04 |
| mfcd09837787 |
| SW219198-2 |
| 179474-81-8 (free base) |
| AS-19549 |
| BCP02177 |
| Q68484 |
| 7-benzofurancarboxamide, 4-amino-5-chloro-2,3-dihydro-n-[1-(3-methoxypropyl)-4-piperidinyl]- |
| HMS3884P20 |
| HMS3748M09 |
| CCG-268257 |
| SY097702 |
| a06ax05 |
| prucalopridum |
| prucaloprida |
| prucalopride (mart.) |
| P2467 |
| EN300-7393093 |
Prucalopride is a prokinetic drug, that has been commercially available in recent years for the treatment of chronically constipated adults. It is a serotonin receptor agonist that stimulates gastrointestinal motility and provides propulsive force for defecation.
Prucalopride is effective, has a good safety profile, and is well tolerated for the treatment of men with chronic constipation. It has a stimulatory effect on gastrointestinal motility and transit, as established by in vivo and in vitro studies.
Prucalopride has been used in adults with gastroparesis, accelerating gastric emptying. It has no major effect on the number of propagating contractions but increases HAPCs amplitude (p = 0.01).
Prucalopride promotes secondary peristalsis by stimulating 5-hydroxytrypatamine 4 receptors in the esophagus. It also promotes a significant neuroprotection against oxidative-mediated proapoptotic mechanisms.
Prucalopride treatment resulted in a mean bowel movement frequency of 6.8/week, normal stool consistency, and reduced frequency of fecal incontinence. Treatment was significantly as-sociated with diarrhea, headache, and nausea (p<0.001), but not with abdominal pain.
Among 1,750 patients with CIC who received prucalopride (2-4 mg) in 5 phase 3 studies, no trends in CV adverse events, electrocardiogram parameters, or blood pressure were documented.
Co-administration of prucalopride with an oral contraceptive did not result in any clinically meaningful pharmacokinetic interactions and was well tolerated. Compared to females, males exhibited a slightly lower exposure of the drug but similar changes of bowel habits were observed in both genders.
| Excerpt | Reference | Relevance |
|---|---|---|
| "78 ng/ml with a median time to Cmax (tmax) of 2 hours and resulted in an area under concentration-time curve (AUC0-∞) of 89." | ( Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhong, W, 2012) | 0.63 |
| " Compared to females, males exhibited a slightly lower exposure of prucalopride but similar changes of bowel habits were observed in both genders suggesting the inter-gender pharmacokinetic differences are not clinically relevant." | ( Pharmacokinetics of single and repeated oral doses prucalopride in healthy Chinese volunteers. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhong, W, 2012) | 0.87 |
| "Co-administration of prucalopride with an oral contraceptive did not result in any clinically meaningful pharmacokinetic interactions and was well tolerated." | ( Effect of prucalopride on the pharmacokinetics of oral contraceptives in healthy women. Ausma, J; Boterman, M; Hoppenbrouwers, M; Van de Velde, V; Vandeplassche, L, 2013) | 1.11 |
| " The aim of this study was to investigate the pharmacokinetic properties and excretion of prucalopride in healthy individuals, using a microtracer approach with (14)C radioactivity detection using liquid scintillation counting and accelerator mass spectrometry." | ( A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers. Ding, J; Dragone, J; Flach, S; Getsy, J; Pankratz, T; Pennick, M; Scarfe, G; Seymour, M; Troy, S, 2016) | 0.88 |
| "The objectives of the present study were to evaluate the bioequivalence of 2 tablet formulations of prucalopride, generic and branded, and to investigate relevant pharmacokinetic and safety profiles." | ( Pharmacokinetics, Bioequivalence, and Safety Studies of Prucalopride in Healthy Chinese Subjects. Chen, H; Huang, X; Wang, C; Xia, Y; Yu, C; Yu, X; Zhang, D; Zhang, X; Zheng, X; Zhou, Z, 2020) | 1.02 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Prucalopride was well absorbed and excreted mainly by the kidneys, including both passive and active transporter mechanisms." | ( A Phase I Study to Investigate the Absorption, Pharmacokinetics, and Excretion of [(14)C]Prucalopride After a Single Oral Dose in Healthy Volunteers. Ding, J; Dragone, J; Flach, S; Getsy, J; Pankratz, T; Pennick, M; Scarfe, G; Seymour, M; Troy, S, 2016) | 2.1 |
| "The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs." | ( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019) | 0.51 |
There was no additional benefit with the 4 mg/day over the 2mg/day dosage of prucalopride. Colonic pressures were recorded in 10 healthy subjects.
| Excerpt | Relevance | Reference |
|---|---|---|
| "After 1 week of dosing (prucalopride or placebo in a double-blind, randomized, crossover fashion), colonic pressures were recorded in 10 healthy subjects using a solid-state pressure catheter with six sensors spaced 10 cm apart." | ( The effects of the specific 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Akkermans, LM; Andriesse, GI; De Schryver, AM; Gooszen, HG; Samsom, M; Smout, AJ, 2002) | 0.87 |
| " There was no additional benefit with the 4 mg/day over the 2 mg/day dosage of prucalopride." | ( Prucalopride. Frampton, JE, 2009) | 2.02 |
| " Dosing information is however needed to establish its actual clinical efficacy and its proper effects on the large bowel in these animals." | ( Effects of Single-Dose Prucalopride on Intestinal Hypomotility in Horses: Preliminary Observations. Bassotti, G; Faillace, V; Fettucciari, K; Fratini, M; Laus, F; Paggi, E; Spaterna, A; Tesei, B, 2017) | 0.77 |
| Class | Description |
|---|---|
| benzamides | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| acetylcholinesterase | Homo sapiens (human) | Potency | 24.6428 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 37.2212 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.7498 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 36.2092 | 0.0013 | 10.1577 | 42.8575 | AID1259252; AID1259253; AID1259255; AID1259256 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 13.3322 | 0.3758 | 27.4851 | 61.6524 | AID743220 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 33.4915 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| G | Vesicular stomatitis virus | Potency | 2.4545 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 3.4671 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| polyprotein | Zika virus | Potency | 37.2212 | 0.0030 | 8.7949 | 48.0869 | AID1347053 |
| Interferon beta | Homo sapiens (human) | Potency | 2.4545 | 0.0033 | 9.1582 | 39.8107 | AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 2.4545 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 2.4545 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 2.4545 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | Ki | 3.9811 | 0.0000 | 0.8871 | 10.0000 | AID416399 |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 3.9811 | 0.0000 | 0.7411 | 9.9000 | AID416399 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | Ki | 0.2800 | 0.0000 | 0.4439 | 10.0000 | AID416400; AID6272; AID6273 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | EC50 (µMol) | 0.0052 | 0.0001 | 0.2328 | 3.2000 | AID1264125 |
| 5-hydroxytryptamine receptor 4 | Homo sapiens (human) | EC50 (µMol) | 0.0121 | 0.0006 | 0.0879 | 1.1220 | AID1264125; AID1375752; AID1375782 |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | EC50 (µMol) | 0.0260 | 0.0087 | 0.0457 | 0.1023 | AID1264225 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID624236 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT4 | 2001 | European journal of pharmacology, Jun-29, Volume: 423, Issue:1 | The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. |
| AID1346953 | Human 5-HT4 receptor (5-Hydroxytryptamine receptors) | 2001 | European journal of pharmacology, Jun-29, Volume: 423, Issue:1 | The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. |
| AID624236 | Agonists at Human 5-Hydroxytryptamine receptor 5-HT4 | 2000 | Journal of neurochemistry, Feb, Volume: 74, Issue:2 | Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. |
| AID1346953 | Human 5-HT4 receptor (5-Hydroxytryptamine receptors) | 2000 | Journal of neurochemistry, Feb, Volume: 74, Issue:2 | Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variant. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | |||
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | |||
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | |||
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | |||
| AID1375783 | Agonist activity at 5-HT4E receptor (unknown origin) relative to 5-HT | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1264125 | Agonist activity at human 5HT4e receptor expressed in CHO cells assessed as cAMP level after 4 hrs by luciferase reporter gene assay | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | |||
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | |||
| AID706218 | Agonist activity at 5HT4 receptor in rat oesophagus assessed as reversal of carbamylcholine-induced contraction at 10 uM incubated at 7 mins post carbamylcholine-challenge measured after 30 mins relative to 5HT | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID1375753 | Agonist activity at recombinant human 5-HT4E receptor expressed in CHO cells assessed as induction of c-AMP accumulation after 4 hrs by luciferase reporter assay relative to 5-HT | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID706215 | Agonist activity at rat 5HT4E receptor expressed in HEK293 cells relative to 5HT | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID6273 | Tested for selectivity for 5-hydroxytryptamine 4 receptor | 2003 | Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3 | 5-HT4 receptor ligands: applications and new prospects. |
| AID1375760 | Ratio of drug level in Wistar rat brain to plasma at 10 mg/kg, po measured at 1 hr by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | |||
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | |||
| AID416400 | Binding affinity at 5HT4 receptor | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | |||
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | |||
| AID1375752 | Agonist activity at recombinant human 5-HT4E receptor expressed in CHO cells assessed as induction of c-AMP accumulation after 4 hrs by luciferase reporter assay | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1264126 | Agonist activity at human 5HT4e receptor expressed in CHO cells assessed as cAMP level after 4 hrs by luciferase reporter gene assay relative to 5-HT | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. |
| AID1375758 | AUC in Wistar rat at 3 mg/kg, po or 1 mg/kg, iv by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID706211 | Receptor occupancy of 5HT4 receptor in Sprague-Dawley rat brain at 10 mg/kg, sc at 1 hr | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID1375774 | In vivo partial agonist activity at 5-HT4 receptor in C57BL/6J mouse assessed as increase in cortical sAPPalpha levels at 10 mg/kg, sc after 60 to 90 mins by ELISA relative to control | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1375757 | Cmax in Wistar rat at 3 mg/kg, po or 1 mg/kg, iv by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1375755 | Drug metabolism in human liver microsomes after 30 mins by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | |||
| AID706217 | Agonist activity at rat 5HT4L receptor expressed in HEK293 cells relative to 5HT | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID706212 | Procognitive activity in Sprague-Dawley rat assessed as increase in acetylcholine level in prefrontal cortex at 10 mg/kg, sc after 3 hrs by brain microdialysis relative to control | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | |||
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | |||
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | |||
| AID1375782 | Agonist activity at 5-HT4E receptor (unknown origin) | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1375754 | Drug metabolism in rat liver microsomes after 30 mins by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID706216 | Agonist activity at rat 5HT4S receptor expressed in HEK293 cells relative to 5HT | 2012 | Journal of medicinal chemistry, Nov-08, Volume: 55, Issue:21 | Identification of multiple 5-HT₄ partial agonist clinical candidates for the treatment of Alzheimer's disease. |
| AID1375756 | Oral bioavailability in Wistar rat at 3 mg/kg by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID416399 | Binding affinity at 5HT3 receptor | 2009 | Bioorganic & medicinal chemistry, Mar-15, Volume: 17, Issue:6 | Novel antagonists of serotonin-4 receptors: synthesis and biological evaluation of pyrrolothienopyrazines. |
| AID6272 | Tested for agonist activity against 5-hydroxytryptamine 4 receptor | 2003 | Journal of medicinal chemistry, Jan-30, Volume: 46, Issue:3 | 5-HT4 receptor ligands: applications and new prospects. |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | |||
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | |||
| AID1264225 | Agonist activity at rat 5HT4e receptor expressed in HEK293 cells assessed as cAMP level after 30 mins by HTRF assay | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. |
| AID1375759 | Clearance in Wistar rat at 1 mg/kg, iv by LC-MS/MS method | 2018 | Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11 | Synthesis, Structure-Activity Relationships, and Preclinical Evaluation of Heteroaromatic Amides and 1,3,4-Oxadiazole Derivatives as 5-HT |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | |||
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | |||
| AID1264226 | Agonist activity at rat 5HT4e receptor expressed in HEK293 cells assessed as cAMP level after 30 mins by HTRF assay relative to 5-HT | 2015 | European journal of medicinal chemistry, Oct-20, Volume: 103 | Synthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | |||
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.87) | 18.2507 |
| 2000's | 51 (22.08) | 29.6817 |
| 2010's | 137 (59.31) | 24.3611 |
| 2020's | 41 (17.75) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (94.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 57 (23.95%) | 5.53% |
| Reviews | 46 (19.33%) | 6.00% |
| Case Studies | 10 (4.20%) | 4.05% |
| Observational | 1 (0.42%) | 0.25% |
| Other | 124 (52.10%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prucalopride (Resolor) Tablets in Participants With Chronic Constipation [NCT01116206] | Phase 3 | 507 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| The Effect of a Single Dose of Prucalopride on Emotional Processing in Healthy Volunteers [NCT03863366] | 41 participants (Actual) | Interventional | 2017-02-07 | Completed | |||
| A Study to Evaluate the Long-Term Tolerability and Safety of Oral Prucalopride Administered to Patients With Chronic Constipation [NCT01070615] | Phase 3 | 693 participants (Actual) | Interventional | 1998-06-30 | Completed | ||
| Optimization of the Bowel Preparation Regimen for Colon Capsule Endoscopy Procedure [NCT05726097] | Phase 3 | 147 participants (Anticipated) | Interventional | 2023-02-01 | Recruiting | ||
| Double-dummy, Double-blind, Randomised, Parallel Group, Controlled Comparative Study of Polyethylene Glycol (PEG)Plus Electrolytes Versus Prucalopride in Females With Chronic Constipation Who Failed Adequate Relief With Laxatives [NCT01251822] | Phase 3 | 240 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| The Effect of 2mg Sub-acute Prucalopride on Cognition and Emotional Processing in Participants Recovered From Depression [NCT05220228] | Early Phase 1 | 50 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | ||
| A Placebo-controlled Trial With Prucalopride for the Treatment of Typical Reflux Symptoms in Patients With Gastro-esophageal Reflux Disease With Incomplete Proton Pump Inhibitor Response [NCT03676374] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-18 | Recruiting | ||
| Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial [NCT02031081] | Phase 2/Phase 3 | 15 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC) [NCT02228616] | Phase 4 | 280 participants (Actual) | Interventional | 2014-10-14 | Completed | ||
| Evaluation of Pharmacokinetics, Safety and Tolerability of a Single Dose of Prucalopride, in Subjects With Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects [NCT01134185] | Phase 1 | 24 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, Two-Way Cross-Over in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Prucalopride at Steady-State [NCT00793429] | Phase 1 | 0 participants | Interventional | Completed | |||
| The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial [NCT02806206] | Phase 4 | 122 participants (Anticipated) | Interventional | 2016-07-31 | Not yet recruiting | ||
| The Effect of Prucalopride (Resolor®) on Gastric Motor Function and Gastric Sensitivity [NCT04429802] | 17 participants (Actual) | Interventional | 2013-09-26 | Completed | |||
| A Randomized, Double-blind/Open-label, Placebo/Active-controlled, Single/Multiple Dose, Parallel, Phase 1/2a Trial to Evaluate the Safety, Tolerability, PK , PD of YH12852 in Healthy Subjects and Patients With Functional Constipation [NCT02538367] | Phase 1/Phase 2 | 120 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Phase 3, Multicenter, Randomized Study With 2 Different Doses of Prucalopride Administered to Male and Female Pediatric Subjects Aged 6 Months to 17 Years With Functional Constipation, Consisting of a 12-week Double-blind, Placebo-controlled Part (Part A) [NCT04759833] | Phase 3 | 175 participants (Actual) | Interventional | 2021-08-02 | Terminated(stopped due to Data Monitoring Committe (DMC) decision; terminated due to futility, with no safety concerns; FDA agreement to terminate the study.) | ||
| The Effect of Prucalopride on the Plasma Levels of Oral Contraceptives (Ethinylestradiol and Norethisterone) in Healthy Subjects [NCT01036893] | Phase 1 | 16 participants (Anticipated) | Interventional | 2009-12-31 | Completed | ||
| A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation [NCT00617513] | Phase 2 | 174 participants (Actual) | Interventional | 1995-03-31 | Completed | ||
| A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Prucalopride in Male Subjects With Chronic Constipation [NCT01147926] | Phase 3 | 374 participants (Actual) | Interventional | 2010-09-23 | Completed | ||
| A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation [NCT00596596] | Phase 2 | 313 participants (Actual) | Interventional | 1996-09-30 | Completed | ||
| A Phase I Thorough QT/QTc Study To Evaluate The Effect of Therapeutic and Supratherapeutic Multiple Doses of Prucalopride on Cardiac Repolarisation in Healthy Male and Female Volunteers [NCT00903747] | Phase 1 | 120 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Study to Evaluate the Long-Term Tolerability, Safety, Patient Satisfaction, Pharmacokinetics, and Use Patterns of Oral Prucalopride Tablets in Patients With Chronic Constipation [NCT00987844] | Phase 3 | 1,775 participants (Actual) | Interventional | 1998-07-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Tolerability of Oral Once-Daily Prucalopride (R108512) Solution in Constipated Elderly Subjects Living in a Nursing Facility [NCT00627692] | Phase 2 | 100 participants (Actual) | Interventional | 1999-02-28 | Completed | ||
| Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule [NCT01864915] | Phase 3 | 60 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites? [NCT01869751] | 0 participants (Actual) | Observational | 2013-05-31 | Withdrawn(stopped due to failure to recruit patients) | |||
| A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects [NCT01870674] | Phase 1 | 127 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Health Related Quality of Life in Female Patients With Chronic Constipation [NCT01902537] | 150 participants (Actual) | Observational | 2012-08-31 | Completed | |||
| A Randomized, Controlled, Double-blind Efficacy and Tolerability Study Of Prucalopride For The Treatment Of Postoperative Ileus In Patients Undergoing Gastrointestinal Surgery [NCT02004652] | Phase 2 | 110 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| A 12-week, Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride in Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation [NCT01117051] | Phase 3 | 174 participants (Actual) | Interventional | 2010-05-19 | Terminated(stopped due to The study was stopped by the sponsor based on a non-safety related business priority decision) | ||
| A Two-Period, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of re-Treatment of Prucalopride on Efficacy and Safety in Subjects With Chronic Constipation. [NCT00598338] | Phase 3 | 516 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| [NCT02781493] | Phase 4 | 600 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects [NCT01807000] | Phase 1 | 6 participants (Actual) | Interventional | 2013-03-18 | Completed | ||
| Study to Evaluate the Effect of a 1 mg o.d. Dose of Prucalopride in Patients With Chronic Idiopathic Constipation [NCT00575614] | Phase 2 | 87 participants (Actual) | Interventional | 1997-04-30 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Severe Chronic Constipation [NCT00576511] | Phase 2 | 53 participants (Actual) | Interventional | 1994-12-31 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dose-Titration on the Safety and Efficacy and R108512 Tablets in Subjects With Chronic Constipation [NCT00577018] | Phase 3 | 755 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects [NCT03279341] | Phase 4 | 10 participants (Actual) | Interventional | 2012-12-03 | Completed | ||
| A Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Quality-of-Life of R108512 Tablets in Elderly Subjects With Chronic Constipation [NCT00487422] | Phase 3 | 303 participants (Actual) | Interventional | 1998-10-31 | Completed | ||
| A Randomized Double-blind Placebo Controlled Trial of Prucalopride to Reduce the Duration of Postoperative Ileus in Patients Undergoing Elective Colorectal Surgery [NCT02947269] | Phase 3 | 150 participants (Actual) | Interventional | 2017-10-25 | Completed | ||
| An Open-label Follow-up Study of 0.01 mg/kg/Day to 0.03 mg/kg/Day Prucalopride (R108512) Oral Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR), Who Participated in the PRU-USA-12. [NCT01670669] | Phase 1 | 37 participants (Actual) | Interventional | 1998-11-30 | Completed | ||
| The Effect of Prucalopride Succinate on Gastrointestinal Motility After Laparoscopic Gastrectomy : Prospective Double Blind Case-control Study [NCT05966246] | 106 participants (Actual) | Interventional | 2022-01-25 | Completed | |||
| A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation. [NCT00483886] | Phase 3 | 620 participants (Actual) | Interventional | 1998-04-30 | Completed | ||
| A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Prucalopride (R108512) Tablets in Subjects With Chronic Constipation [NCT00488137] | Phase 3 | 716 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Double-Blind, Placebo-Controlled, 2-Way Cross-Over Trial in Healthy Volunteers, to Evaluate the Pharmacokinetics, Tolerability and Cardiac Safety of Oral Prucalopride at Steady State, After up-Titration to a Maximum of 20 mg. [NCT00488215] | Phase 1 | 32 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| The Effect of Seven Day Prucalopride Administration on Emotional Processing in Healthy Volunteers [NCT03572790] | 50 participants (Actual) | Interventional | 2018-06-11 | Completed | |||
| A Double-Blind Placebo-Controlled Dose-Finding Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation [NCT00631813] | Phase 2 | 253 participants (Actual) | Interventional | 1995-11-30 | Completed | ||
| A Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of R108512 Tablets in Subjects With Chronic Constipation [NCT00485940] | Phase 3 | 641 participants (Actual) | Interventional | 1998-03-31 | Completed | ||
| A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Quality of Life, Safety and Tolerability of Long-term Treatment (24 Weeks) With Prucalopride in Subjects Aged ≥18 Years With Chronic Constipation [NCT01424228] | Phase 4 | 364 participants (Actual) | Interventional | 2011-04-06 | Completed | ||
| Trial Consisting of an 8-week Double-blind Placebo-controlled Part to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of Prucalopride in Paediatric Subjects With Functional Constipation, Aged ≥6 Months to <18 Years, Followed by a 16-week Open [NCT01330381] | Phase 3 | 215 participants (Actual) | Interventional | 2011-04-28 | Completed | ||
| Improving Bowel Preparation for the Colon Capsule: Picosalax and Prucalopride vs. PEG and Prucalopride [NCT01655095] | Phase 3 | 20 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation [NCT01692132] | 0 participants (Actual) | Observational | 2013-02-28 | Withdrawn(stopped due to The company decided to cancel this study in conformity with PH FDA Circular 2013-004) | |||
| Single Dose Pharmacokinetic Trial of Oral Prucalopride (R093877) in Subjects With Mild, Moderate and Severe Renal Impairment [NCT01674192] | Phase 1 | 34 participants (Actual) | Interventional | 1997-07-31 | Completed | ||
| The Impact of Upper Gastrointestinal Dysmotility on Aspiration-associated Symptoms [NCT05455359] | Phase 4 | 120 participants (Anticipated) | Interventional | 2022-07-18 | Not yet recruiting | ||
| The Effect of Prucalopride on Gastric Emptying in Intensive Care Unit Patients [NCT05496179] | Phase 1/Phase 2 | 70 participants (Actual) | Interventional | 2022-03-07 | Completed | ||
| Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway: A Potential New Therapeutical Intervention for Postoperative Ileus [NCT02425774] | Phase 4 | 30 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study [NCT03244553] | Phase 2 | 28 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Gastric Glitch: a New Functional Disease Treated With Prucalopride and Buspirone in a N-of-1 Double-blind Clinical Trial [NCT05377619] | Phase 1/Phase 2 | 1 participants (Actual) | Interventional | 2022-01-06 | Completed | ||
| Study of Comparative Effectiveness of Prucalopride and Lubiprostone in Constipation Predominant Irritable Bowel Syndrome [NCT04985669] | Phase 4 | 140 participants (Anticipated) | Interventional | 2021-08-15 | Recruiting | ||
| A Single-dose Pharmacokinetic Trial of 0.03 mg/kg R108512 Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR). [NCT01674166] | Phase 1 | 38 participants (Actual) | Interventional | 1998-11-30 | Completed | ||
| An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation [NCT01707667] | Phase 4 | 13 participants (Actual) | Interventional | 2013-02-27 | Completed | ||
| A Randomized Controlled Clinical Trial of Prucaloprude Succinate in Promoting the Recovery of Intestinal Function After Robot-assisted Laparoscopic Radical Cystectomy and Urinary Diversion [NCT05001763] | Phase 2 | 160 participants (Anticipated) | Interventional | 2021-09-01 | Not yet recruiting | ||
| Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying [NCT02510976] | Phase 4 | 30 participants (Anticipated) | Interventional | 2011-11-30 | Recruiting | ||
| The Effects of Prucalopride in Patients With Constipation Predominant Irritable Bowel Syndrome: A Double Blind Placebo Controlled Trial [NCT04757493] | Phase 2/Phase 3 | 160 participants (Anticipated) | Interventional | 2021-03-10 | Recruiting | ||
| Efficacy of Prucalopride in Critically Ill Patients With Paralytic Ileus; a Pilot Randomized Double-blind Controlled Trial [NCT04190173] | Phase 3 | 62 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Multi-center Noninferiority Randomized Controlled Trial [NCT02047045] | 560 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||